Syndax Pharmaceuticals, Inc.

Stage 4 · Declining · week 6

As of Oct 22, 2026, Syndax Pharmaceuticals is in Stage 4, the downtrend phase, now in week 6 (since Sep 17, 2026). It closed at $13.57, 46.0% below its 52-week high and below its 200-day average, which is falling.

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. More about the company

$13.57

+3.19% today

$1.2B · Small cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is SNDX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 17w

S2 15w

S4 26w

S4 19w

S2 25w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S4 17w → S1 6w → S2 15w → S3 11w → S2 8w → S4 26w → S1 2w → S4 19w → S1 5w → S2 8w → S3 2w → S2 25w → S3 9w → S2 2w → S1 6w → S4 5w current

Total tracked: 165 weeks across 16 stage runs.

SNDX among Biotechnology218th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…218	SNDXSyndax Pharmaceuticals, Inc.	Stage 4 · wk 6	46	−23.1%

vs 52W High

-46.0%

$12.90 lo$25.15 hi

46.0% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 6

1w13w26w

Week 6, early Stage 4 decline

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-33.7%

200 DMA: $20.46 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.28x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

-23.1%

-34.8%

-35.4%

YTD

-36.3%

-10.7%

Scan Membership

Breakout Watch

Latest: 2024-07-19

9 appearances in last 60 days. First seen: 2019-05-10.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 6 · Vol 1.28x

2026-10-21S4

Wk 5 · Vol 1.40x

2026-10-20S4

Wk 5 · Vol 2.23x

2026-10-19S4

Wk 5 · Vol 1.27x

2026-10-16S4

Wk 5 · Vol 1.66x

2026-10-15S4

Wk 5 · Vol 1.52x

2026-10-14S4

Wk 4 · Vol 1.78x

2026-10-13S4

Wk 4 · Vol 4.24x

2026-10-12S4

Wk 4 · Vol 1.28x

2026-10-09S4

Wk 4 · Vol 0.92x

2026-10-08S4

Wk 4 · Vol 1.36x

2026-10-07S4

Wk 3 · Vol 1.02x

Moving averages & range

50 DMA

$17.92

200 DMA

$20.46

52W High

$25.15

52W Low

$12.90

5D Low

$12.90

Resistance levels (recent highs)

20d High

$18.80

60d High

$20.78

120d High

$24.84

250d High

$25.15

Next resistance

+38.5%

to 20d High

ROE

-255.9%

Profit margin -87.5%

Dividend Yield

0.00%

P/B 80.3

Syndax Pharmaceuticals: quick answers

What stage is Syndax Pharmaceuticals in?

As of Oct 22, 2026, Syndax Pharmaceuticals (SNDX) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 17, 2026 and is in week 6. What the four stages mean

Is Syndax Pharmaceuticals in an uptrend?

No. Syndax Pharmaceuticals is in a Stage 4 downtrend. It trades 33.7% below its 200-day average, which is falling.

How far is Syndax Pharmaceuticals from its 52-week high?

Syndax Pharmaceuticals closed at $13.57 on Oct 22, 2026, 46.0% below its 52-week high of $25.15. Its 52-week low is $12.90.

How has Syndax Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Syndax Pharmaceuticals is down 10.7% over the past year and down 36.3% so far in 2026.

Which sector and industry is Syndax Pharmaceuticals in?

Syndax Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Syndax Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidate includes Revuforj (revumenib), a menin inhibitor for the treatment of relapsed or refractory R/R acute leukemia; and Niktimvo (axatilimab-csfr), a colony stimulating factor-1 receptor blocking antibody to treat chronic graft-versus-host disease. The company is also developing revumenib for the treatment of R/R acute myeloid leukemia (AML) with a nucleophosmin 1 mutation (mNPM1) and in combination with standard-of-care agents in mNPM1 AML or KMT2Ar acute leukemia, as well as for metastatic colorectal cancer; axatilimab to treat idiopathic pulmonary fibrosis; and Entinostat, a Class 1 HDAC inhibitor. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in New York, New York.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.